Jeremy is passionate about investing today for a healthier tomorrow and bringing tangible benefits to people across the world.
As a veteran in the life sciences/healthcare industry he has been actively supporting the commercialisation of healthcare innovations and helping entrepreneurs build their international businesses over the past 40 years.
Role
Founder and Managing Partner of BioScience Managers, Jeremy brings his decades of international experience to our investment team, to support the identification of investment opportunities and in the strategic assessment of value creation options, in particular through M&A and expansion into new geographies. He actively supports portfolio companies through his executive and non-executive roles.
Experience
Over his career, Jeremy has successfully managed in excess of US$1billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and significant investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. He has served on more than 40 boards of directors in the life science sector, in the UK, Europe, USA, Canada, Japan and Australia.
Qualifications
Jeremy received his MA in Natural Sciences from Trinity College in Dublin and was a research scientist at the Institute of Cancer Research from 1972 to 1973.
Current board positions
Avita Medical Ltd (Australia)
Adherium Ltd (Australia)
BioScience Managers Pty Ltd (Australia)
International Bioscience Managers Ltd (UK)
Bioscience Managers UK Ltd (UK)
Sea Dragon Ltd (New Zealand) (Alternate)
CRiL (Australia)
REX Bionics (Australia)
Smart Matrix Ltd (UK)
Previous board positions
Rothschild Asset Management
Biocompatibles International PLC……sold to BTG PLC
Cantab Pharmaceuticals PLC…..sold to Xenova PLC
Cambridge Research Biochemicals Ltd…sold to Zeneca PLC
Sirna Therapeutics Inc…sold to Merck Inc
Mercia Diagnostics Ltd……sold to Centocor (Johnson and Johnson)
SUGEN Inc……sold to Pharmaxis and Upjohn
Topigen Pharmaceuticals Inc ..sold to Pharmaxis
Delsys Inc……sold to Elan Inc
Angiotech Inc
AMRAD Ltd
Vernalis PLC
Aegera Therapeutics Inc ….sold to Pharmascience
Silence Therapeutics plc (UK)
Bioxyne Ltd (Australia)
Summatix
Armata Pharmaceuticals, Inc
GEN inCode